Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

A Phase I in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Amgen

Protocol Number
20150161

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Blue Bird CRB-401

Protocol Number
Blue Bird CRB-401

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION MM-003)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A PHASE 1 MULTI-CENTER, OPEN-LABEL, DOSE ESCALATION STUDY TO DETERMINE THE PHARMACOKINETICS AND SAFETY OF POMALIDOMIDE WHEN GIVEN IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND IMPAIRED RENAL FUNCTION

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-008

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

A Phase I in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Amgen

Protocol Number
20150161

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Blue Bird CRB-401

Protocol Number
Blue Bird CRB-401

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION MM-003)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A PHASE 1 MULTI-CENTER, OPEN-LABEL, DOSE ESCALATION STUDY TO DETERMINE THE PHARMACOKINETICS AND SAFETY OF POMALIDOMIDE WHEN GIVEN IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND IMPAIRED RENAL FUNCTION

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-008

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

A Phase I in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Amgen

Protocol Number
20150161

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Blue Bird CRB-401

Protocol Number
Blue Bird CRB-401

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION MM-003)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A PHASE 1 MULTI-CENTER, OPEN-LABEL, DOSE ESCALATION STUDY TO DETERMINE THE PHARMACOKINETICS AND SAFETY OF POMALIDOMIDE WHEN GIVEN IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND IMPAIRED RENAL FUNCTION

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-008

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

A Phase I in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Amgen

Protocol Number
20150161

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Blue Bird CRB-401

Protocol Number
Blue Bird CRB-401

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION MM-003)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A PHASE 1 MULTI-CENTER, OPEN-LABEL, DOSE ESCALATION STUDY TO DETERMINE THE PHARMACOKINETICS AND SAFETY OF POMALIDOMIDE WHEN GIVEN IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND IMPAIRED RENAL FUNCTION

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-008

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

A Phase I in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Amgen

Protocol Number
20150161

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Blue Bird CRB-401

Protocol Number
Blue Bird CRB-401

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION MM-003)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A PHASE 1 MULTI-CENTER, OPEN-LABEL, DOSE ESCALATION STUDY TO DETERMINE THE PHARMACOKINETICS AND SAFETY OF POMALIDOMIDE WHEN GIVEN IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND IMPAIRED RENAL FUNCTION

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-008

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

A Phase I in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Amgen

Protocol Number
20150161

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Blue Bird CRB-401

Protocol Number
Blue Bird CRB-401

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION MM-003)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A PHASE 1 MULTI-CENTER, OPEN-LABEL, DOSE ESCALATION STUDY TO DETERMINE THE PHARMACOKINETICS AND SAFETY OF POMALIDOMIDE WHEN GIVEN IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND IMPAIRED RENAL FUNCTION

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-008

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

A Phase I in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Amgen

Protocol Number
20150161

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Blue Bird CRB-401

Protocol Number
Blue Bird CRB-401

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION MM-003)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A PHASE 1 MULTI-CENTER, OPEN-LABEL, DOSE ESCALATION STUDY TO DETERMINE THE PHARMACOKINETICS AND SAFETY OF POMALIDOMIDE WHEN GIVEN IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND IMPAIRED RENAL FUNCTION

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-008

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

A Phase I in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Amgen

Protocol Number
20150161

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Blue Bird CRB-401

Protocol Number
Blue Bird CRB-401

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION MM-003)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A PHASE 1 MULTI-CENTER, OPEN-LABEL, DOSE ESCALATION STUDY TO DETERMINE THE PHARMACOKINETICS AND SAFETY OF POMALIDOMIDE WHEN GIVEN IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND IMPAIRED RENAL FUNCTION

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-008

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

A Phase I in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Amgen

Protocol Number
20150161

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Blue Bird CRB-401

Protocol Number
Blue Bird CRB-401

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION MM-003)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A PHASE 1 MULTI-CENTER, OPEN-LABEL, DOSE ESCALATION STUDY TO DETERMINE THE PHARMACOKINETICS AND SAFETY OF POMALIDOMIDE WHEN GIVEN IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND IMPAIRED RENAL FUNCTION

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-008

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

A Phase I in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Amgen

Protocol Number
20150161

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Blue Bird CRB-401

Protocol Number
Blue Bird CRB-401

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION MM-003)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A PHASE 1 MULTI-CENTER, OPEN-LABEL, DOSE ESCALATION STUDY TO DETERMINE THE PHARMACOKINETICS AND SAFETY OF POMALIDOMIDE WHEN GIVEN IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND IMPAIRED RENAL FUNCTION

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-008

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

A Phase I in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Amgen

Protocol Number
20150161

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Blue Bird CRB-401

Protocol Number
Blue Bird CRB-401

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION MM-003)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A PHASE 1 MULTI-CENTER, OPEN-LABEL, DOSE ESCALATION STUDY TO DETERMINE THE PHARMACOKINETICS AND SAFETY OF POMALIDOMIDE WHEN GIVEN IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND IMPAIRED RENAL FUNCTION

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-008

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

A Phase I in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Amgen

Protocol Number
20150161

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Blue Bird CRB-401

Protocol Number
Blue Bird CRB-401

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION MM-003)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A PHASE 1 MULTI-CENTER, OPEN-LABEL, DOSE ESCALATION STUDY TO DETERMINE THE PHARMACOKINETICS AND SAFETY OF POMALIDOMIDE WHEN GIVEN IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND IMPAIRED RENAL FUNCTION

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-008

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

A Phase I in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Amgen

Protocol Number
20150161

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Blue Bird CRB-401

Protocol Number
Blue Bird CRB-401

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION MM-003)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A PHASE 1 MULTI-CENTER, OPEN-LABEL, DOSE ESCALATION STUDY TO DETERMINE THE PHARMACOKINETICS AND SAFETY OF POMALIDOMIDE WHEN GIVEN IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND IMPAIRED RENAL FUNCTION

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-008

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

A Phase I in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Amgen

Protocol Number
20150161

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Blue Bird CRB-401

Protocol Number
Blue Bird CRB-401

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION MM-003)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A PHASE 1 MULTI-CENTER, OPEN-LABEL, DOSE ESCALATION STUDY TO DETERMINE THE PHARMACOKINETICS AND SAFETY OF POMALIDOMIDE WHEN GIVEN IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND IMPAIRED RENAL FUNCTION

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-008

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

A Phase I in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Amgen

Protocol Number
20150161

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Blue Bird CRB-401

Protocol Number
Blue Bird CRB-401

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION MM-003)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A PHASE 1 MULTI-CENTER, OPEN-LABEL, DOSE ESCALATION STUDY TO DETERMINE THE PHARMACOKINETICS AND SAFETY OF POMALIDOMIDE WHEN GIVEN IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND IMPAIRED RENAL FUNCTION

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-008

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

A Phase I in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Amgen

Protocol Number
20150161

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Blue Bird CRB-401

Protocol Number
Blue Bird CRB-401

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION MM-003)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A PHASE 1 MULTI-CENTER, OPEN-LABEL, DOSE ESCALATION STUDY TO DETERMINE THE PHARMACOKINETICS AND SAFETY OF POMALIDOMIDE WHEN GIVEN IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND IMPAIRED RENAL FUNCTION

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-008

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

A Phase I in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Amgen

Protocol Number
20150161

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Blue Bird CRB-401

Protocol Number
Blue Bird CRB-401

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION MM-003)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A PHASE 1 MULTI-CENTER, OPEN-LABEL, DOSE ESCALATION STUDY TO DETERMINE THE PHARMACOKINETICS AND SAFETY OF POMALIDOMIDE WHEN GIVEN IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND IMPAIRED RENAL FUNCTION

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-008

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

A Phase I in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Amgen

Protocol Number
20150161

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Blue Bird CRB-401

Protocol Number
Blue Bird CRB-401

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION MM-003)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A PHASE 1 MULTI-CENTER, OPEN-LABEL, DOSE ESCALATION STUDY TO DETERMINE THE PHARMACOKINETICS AND SAFETY OF POMALIDOMIDE WHEN GIVEN IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND IMPAIRED RENAL FUNCTION

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-008

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

A Phase I in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Amgen

Protocol Number
20150161

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Blue Bird CRB-401

Protocol Number
Blue Bird CRB-401

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION MM-003)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A PHASE 1 MULTI-CENTER, OPEN-LABEL, DOSE ESCALATION STUDY TO DETERMINE THE PHARMACOKINETICS AND SAFETY OF POMALIDOMIDE WHEN GIVEN IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND IMPAIRED RENAL FUNCTION

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-008

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

A Phase I in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Amgen

Protocol Number
20150161

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Blue Bird CRB-401

Protocol Number
Blue Bird CRB-401

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION MM-003)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A PHASE 1 MULTI-CENTER, OPEN-LABEL, DOSE ESCALATION STUDY TO DETERMINE THE PHARMACOKINETICS AND SAFETY OF POMALIDOMIDE WHEN GIVEN IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND IMPAIRED RENAL FUNCTION

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-008

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

A Phase I in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Amgen

Protocol Number
20150161

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Blue Bird CRB-401

Protocol Number
Blue Bird CRB-401

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION MM-003)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A PHASE 1 MULTI-CENTER, OPEN-LABEL, DOSE ESCALATION STUDY TO DETERMINE THE PHARMACOKINETICS AND SAFETY OF POMALIDOMIDE WHEN GIVEN IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND IMPAIRED RENAL FUNCTION

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-008

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

A Phase I in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Amgen

Protocol Number
20150161

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Blue Bird CRB-401

Protocol Number
Blue Bird CRB-401

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION MM-003)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A PHASE 1 MULTI-CENTER, OPEN-LABEL, DOSE ESCALATION STUDY TO DETERMINE THE PHARMACOKINETICS AND SAFETY OF POMALIDOMIDE WHEN GIVEN IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND IMPAIRED RENAL FUNCTION

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-008

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

A Phase I in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Amgen

Protocol Number
20150161

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Blue Bird CRB-401

Protocol Number
Blue Bird CRB-401

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION MM-003)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A PHASE 1 MULTI-CENTER, OPEN-LABEL, DOSE ESCALATION STUDY TO DETERMINE THE PHARMACOKINETICS AND SAFETY OF POMALIDOMIDE WHEN GIVEN IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND IMPAIRED RENAL FUNCTION

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-008

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

A Phase I in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Amgen

Protocol Number
20150161

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Blue Bird CRB-401

Protocol Number
Blue Bird CRB-401

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION MM-003)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A PHASE 1 MULTI-CENTER, OPEN-LABEL, DOSE ESCALATION STUDY TO DETERMINE THE PHARMACOKINETICS AND SAFETY OF POMALIDOMIDE WHEN GIVEN IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND IMPAIRED RENAL FUNCTION

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-008

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

A Phase I in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Amgen

Protocol Number
20150161

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Blue Bird CRB-401

Protocol Number
Blue Bird CRB-401

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION MM-003)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A PHASE 1 MULTI-CENTER, OPEN-LABEL, DOSE ESCALATION STUDY TO DETERMINE THE PHARMACOKINETICS AND SAFETY OF POMALIDOMIDE WHEN GIVEN IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND IMPAIRED RENAL FUNCTION

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-008

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

A Phase I in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Amgen

Protocol Number
20150161

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Blue Bird CRB-401

Protocol Number
Blue Bird CRB-401

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION MM-003)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A PHASE 1 MULTI-CENTER, OPEN-LABEL, DOSE ESCALATION STUDY TO DETERMINE THE PHARMACOKINETICS AND SAFETY OF POMALIDOMIDE WHEN GIVEN IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND IMPAIRED RENAL FUNCTION

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-008

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

A Phase I in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Amgen

Protocol Number
20150161

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Blue Bird CRB-401

Protocol Number
Blue Bird CRB-401

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION MM-003)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A PHASE 1 MULTI-CENTER, OPEN-LABEL, DOSE ESCALATION STUDY TO DETERMINE THE PHARMACOKINETICS AND SAFETY OF POMALIDOMIDE WHEN GIVEN IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND IMPAIRED RENAL FUNCTION

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-008

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

A Phase I in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Amgen

Protocol Number
20150161

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Blue Bird CRB-401

Protocol Number
Blue Bird CRB-401

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION MM-003)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A PHASE 1 MULTI-CENTER, OPEN-LABEL, DOSE ESCALATION STUDY TO DETERMINE THE PHARMACOKINETICS AND SAFETY OF POMALIDOMIDE WHEN GIVEN IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND IMPAIRED RENAL FUNCTION

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-008

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

A Phase I in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Amgen

Protocol Number
20150161

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Blue Bird CRB-401

Protocol Number
Blue Bird CRB-401

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION MM-003)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A PHASE 1 MULTI-CENTER, OPEN-LABEL, DOSE ESCALATION STUDY TO DETERMINE THE PHARMACOKINETICS AND SAFETY OF POMALIDOMIDE WHEN GIVEN IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND IMPAIRED RENAL FUNCTION

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-008

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

A Phase I in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Amgen

Protocol Number
20150161

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Blue Bird CRB-401

Protocol Number
Blue Bird CRB-401

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION MM-003)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A PHASE 1 MULTI-CENTER, OPEN-LABEL, DOSE ESCALATION STUDY TO DETERMINE THE PHARMACOKINETICS AND SAFETY OF POMALIDOMIDE WHEN GIVEN IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND IMPAIRED RENAL FUNCTION

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-008

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

A Phase I in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Amgen

Protocol Number
20150161

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Blue Bird CRB-401

Protocol Number
Blue Bird CRB-401

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION MM-003)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A PHASE 1 MULTI-CENTER, OPEN-LABEL, DOSE ESCALATION STUDY TO DETERMINE THE PHARMACOKINETICS AND SAFETY OF POMALIDOMIDE WHEN GIVEN IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND IMPAIRED RENAL FUNCTION

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-008

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

A Phase I in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Amgen

Protocol Number
20150161

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Blue Bird CRB-401

Protocol Number
Blue Bird CRB-401

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION MM-003)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A PHASE 1 MULTI-CENTER, OPEN-LABEL, DOSE ESCALATION STUDY TO DETERMINE THE PHARMACOKINETICS AND SAFETY OF POMALIDOMIDE WHEN GIVEN IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND IMPAIRED RENAL FUNCTION

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-008

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

A Phase I in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Amgen

Protocol Number
20150161

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Blue Bird CRB-401

Protocol Number
Blue Bird CRB-401

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION MM-003)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A PHASE 1 MULTI-CENTER, OPEN-LABEL, DOSE ESCALATION STUDY TO DETERMINE THE PHARMACOKINETICS AND SAFETY OF POMALIDOMIDE WHEN GIVEN IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND IMPAIRED RENAL FUNCTION

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-008

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

A Phase I in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Amgen

Protocol Number
20150161

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Blue Bird CRB-401

Protocol Number
Blue Bird CRB-401

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION MM-003)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A PHASE 1 MULTI-CENTER, OPEN-LABEL, DOSE ESCALATION STUDY TO DETERMINE THE PHARMACOKINETICS AND SAFETY OF POMALIDOMIDE WHEN GIVEN IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND IMPAIRED RENAL FUNCTION

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-008

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

A Phase I in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Amgen

Protocol Number
20150161

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Blue Bird CRB-401

Protocol Number
Blue Bird CRB-401

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION MM-003)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A PHASE 1 MULTI-CENTER, OPEN-LABEL, DOSE ESCALATION STUDY TO DETERMINE THE PHARMACOKINETICS AND SAFETY OF POMALIDOMIDE WHEN GIVEN IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND IMPAIRED RENAL FUNCTION

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-008

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

A Phase I in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Amgen

Protocol Number
20150161

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Blue Bird CRB-401

Protocol Number
Blue Bird CRB-401

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION MM-003)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A PHASE 1 MULTI-CENTER, OPEN-LABEL, DOSE ESCALATION STUDY TO DETERMINE THE PHARMACOKINETICS AND SAFETY OF POMALIDOMIDE WHEN GIVEN IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND IMPAIRED RENAL FUNCTION

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-008

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

A Phase I in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Amgen

Protocol Number
20150161

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Blue Bird CRB-401

Protocol Number
Blue Bird CRB-401

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION MM-003)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A PHASE 1 MULTI-CENTER, OPEN-LABEL, DOSE ESCALATION STUDY TO DETERMINE THE PHARMACOKINETICS AND SAFETY OF POMALIDOMIDE WHEN GIVEN IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND IMPAIRED RENAL FUNCTION

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-008

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

A Phase I in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Amgen

Protocol Number
20150161

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Blue Bird CRB-401

Protocol Number
Blue Bird CRB-401

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION MM-003)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A PHASE 1 MULTI-CENTER, OPEN-LABEL, DOSE ESCALATION STUDY TO DETERMINE THE PHARMACOKINETICS AND SAFETY OF POMALIDOMIDE WHEN GIVEN IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND IMPAIRED RENAL FUNCTION

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-008

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

A Phase I in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Amgen

Protocol Number
20150161

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Blue Bird CRB-401

Protocol Number
Blue Bird CRB-401

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION MM-003)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A PHASE 1 MULTI-CENTER, OPEN-LABEL, DOSE ESCALATION STUDY TO DETERMINE THE PHARMACOKINETICS AND SAFETY OF POMALIDOMIDE WHEN GIVEN IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND IMPAIRED RENAL FUNCTION

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-008

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

A Phase I in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Amgen

Protocol Number
20150161

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Blue Bird CRB-401

Protocol Number
Blue Bird CRB-401

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION MM-003)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A PHASE 1 MULTI-CENTER, OPEN-LABEL, DOSE ESCALATION STUDY TO DETERMINE THE PHARMACOKINETICS AND SAFETY OF POMALIDOMIDE WHEN GIVEN IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND IMPAIRED RENAL FUNCTION

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-008

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

A Phase I in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Amgen

Protocol Number
20150161

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Blue Bird CRB-401

Protocol Number
Blue Bird CRB-401

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION MM-003)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A PHASE 1 MULTI-CENTER, OPEN-LABEL, DOSE ESCALATION STUDY TO DETERMINE THE PHARMACOKINETICS AND SAFETY OF POMALIDOMIDE WHEN GIVEN IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND IMPAIRED RENAL FUNCTION

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-008

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

A Phase I in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Amgen

Protocol Number
20150161

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Blue Bird CRB-401

Protocol Number
Blue Bird CRB-401

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION MM-003)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A PHASE 1 MULTI-CENTER, OPEN-LABEL, DOSE ESCALATION STUDY TO DETERMINE THE PHARMACOKINETICS AND SAFETY OF POMALIDOMIDE WHEN GIVEN IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND IMPAIRED RENAL FUNCTION

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-008

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

A Phase I in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Amgen

Protocol Number
20150161

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Blue Bird CRB-401

Protocol Number
Blue Bird CRB-401

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION MM-003)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A PHASE 1 MULTI-CENTER, OPEN-LABEL, DOSE ESCALATION STUDY TO DETERMINE THE PHARMACOKINETICS AND SAFETY OF POMALIDOMIDE WHEN GIVEN IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND IMPAIRED RENAL FUNCTION

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-008

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

A Phase I in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Amgen

Protocol Number
20150161

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Blue Bird CRB-401

Protocol Number
Blue Bird CRB-401

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION MM-003)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A PHASE 1 MULTI-CENTER, OPEN-LABEL, DOSE ESCALATION STUDY TO DETERMINE THE PHARMACOKINETICS AND SAFETY OF POMALIDOMIDE WHEN GIVEN IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND IMPAIRED RENAL FUNCTION

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-008

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

A Phase I in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Amgen

Protocol Number
20150161

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Blue Bird CRB-401

Protocol Number
Blue Bird CRB-401

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION MM-003)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A PHASE 1 MULTI-CENTER, OPEN-LABEL, DOSE ESCALATION STUDY TO DETERMINE THE PHARMACOKINETICS AND SAFETY OF POMALIDOMIDE WHEN GIVEN IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND IMPAIRED RENAL FUNCTION

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-008

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

A Phase I in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Amgen

Protocol Number
20150161

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Blue Bird CRB-401

Protocol Number
Blue Bird CRB-401

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION MM-003)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A PHASE 1 MULTI-CENTER, OPEN-LABEL, DOSE ESCALATION STUDY TO DETERMINE THE PHARMACOKINETICS AND SAFETY OF POMALIDOMIDE WHEN GIVEN IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND IMPAIRED RENAL FUNCTION

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-008

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

A Phase I in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Amgen

Protocol Number
20150161

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Blue Bird CRB-401

Protocol Number
Blue Bird CRB-401

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION MM-003)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A PHASE 1 MULTI-CENTER, OPEN-LABEL, DOSE ESCALATION STUDY TO DETERMINE THE PHARMACOKINETICS AND SAFETY OF POMALIDOMIDE WHEN GIVEN IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND IMPAIRED RENAL FUNCTION

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-008

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

A Phase I in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Amgen

Protocol Number
20150161

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Blue Bird CRB-401

Protocol Number
Blue Bird CRB-401

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION MM-003)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A PHASE 1 MULTI-CENTER, OPEN-LABEL, DOSE ESCALATION STUDY TO DETERMINE THE PHARMACOKINETICS AND SAFETY OF POMALIDOMIDE WHEN GIVEN IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND IMPAIRED RENAL FUNCTION

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-008

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

A Phase I in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Amgen

Protocol Number
20150161

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Blue Bird CRB-401

Protocol Number
Blue Bird CRB-401

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION MM-003)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A PHASE 1 MULTI-CENTER, OPEN-LABEL, DOSE ESCALATION STUDY TO DETERMINE THE PHARMACOKINETICS AND SAFETY OF POMALIDOMIDE WHEN GIVEN IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND IMPAIRED RENAL FUNCTION

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-008

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

A Phase I in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Amgen

Protocol Number
20150161

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Blue Bird CRB-401

Protocol Number
Blue Bird CRB-401

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION MM-003)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A PHASE 1 MULTI-CENTER, OPEN-LABEL, DOSE ESCALATION STUDY TO DETERMINE THE PHARMACOKINETICS AND SAFETY OF POMALIDOMIDE WHEN GIVEN IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND IMPAIRED RENAL FUNCTION

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-008

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

A Phase I in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Amgen

Protocol Number
20150161

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Blue Bird CRB-401

Protocol Number
Blue Bird CRB-401

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION MM-003)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A PHASE 1 MULTI-CENTER, OPEN-LABEL, DOSE ESCALATION STUDY TO DETERMINE THE PHARMACOKINETICS AND SAFETY OF POMALIDOMIDE WHEN GIVEN IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND IMPAIRED RENAL FUNCTION

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-008

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

A Phase I in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Amgen

Protocol Number
20150161

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Blue Bird CRB-401

Protocol Number
Blue Bird CRB-401

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION MM-003)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A PHASE 1 MULTI-CENTER, OPEN-LABEL, DOSE ESCALATION STUDY TO DETERMINE THE PHARMACOKINETICS AND SAFETY OF POMALIDOMIDE WHEN GIVEN IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND IMPAIRED RENAL FUNCTION

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-008

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

A Phase I in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Amgen

Protocol Number
20150161

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Blue Bird CRB-401

Protocol Number
Blue Bird CRB-401

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION MM-003)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A PHASE 1 MULTI-CENTER, OPEN-LABEL, DOSE ESCALATION STUDY TO DETERMINE THE PHARMACOKINETICS AND SAFETY OF POMALIDOMIDE WHEN GIVEN IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND IMPAIRED RENAL FUNCTION

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-008

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

A Phase I in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Amgen

Protocol Number
20150161

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Blue Bird CRB-401

Protocol Number
Blue Bird CRB-401

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION MM-003)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A PHASE 1 MULTI-CENTER, OPEN-LABEL, DOSE ESCALATION STUDY TO DETERMINE THE PHARMACOKINETICS AND SAFETY OF POMALIDOMIDE WHEN GIVEN IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND IMPAIRED RENAL FUNCTION

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-008

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

A Phase I in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Amgen

Protocol Number
20150161

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Blue Bird CRB-401

Protocol Number
Blue Bird CRB-401

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION MM-003)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A PHASE 1 MULTI-CENTER, OPEN-LABEL, DOSE ESCALATION STUDY TO DETERMINE THE PHARMACOKINETICS AND SAFETY OF POMALIDOMIDE WHEN GIVEN IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND IMPAIRED RENAL FUNCTION

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-008

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

A Phase I in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Amgen

Protocol Number
20150161

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Blue Bird CRB-401

Protocol Number
Blue Bird CRB-401

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION MM-003)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A PHASE 1 MULTI-CENTER, OPEN-LABEL, DOSE ESCALATION STUDY TO DETERMINE THE PHARMACOKINETICS AND SAFETY OF POMALIDOMIDE WHEN GIVEN IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND IMPAIRED RENAL FUNCTION

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-008

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

A Phase I in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Amgen

Protocol Number
20150161

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Blue Bird CRB-401

Protocol Number
Blue Bird CRB-401

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION MM-003)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A PHASE 1 MULTI-CENTER, OPEN-LABEL, DOSE ESCALATION STUDY TO DETERMINE THE PHARMACOKINETICS AND SAFETY OF POMALIDOMIDE WHEN GIVEN IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND IMPAIRED RENAL FUNCTION

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-008

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

A Phase I in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Amgen

Protocol Number
20150161

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Blue Bird CRB-401

Protocol Number
Blue Bird CRB-401

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION MM-003)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A PHASE 1 MULTI-CENTER, OPEN-LABEL, DOSE ESCALATION STUDY TO DETERMINE THE PHARMACOKINETICS AND SAFETY OF POMALIDOMIDE WHEN GIVEN IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND IMPAIRED RENAL FUNCTION

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-008

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

A Phase I in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Amgen

Protocol Number
20150161

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Blue Bird CRB-401

Protocol Number
Blue Bird CRB-401

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION MM-003)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A PHASE 1 MULTI-CENTER, OPEN-LABEL, DOSE ESCALATION STUDY TO DETERMINE THE PHARMACOKINETICS AND SAFETY OF POMALIDOMIDE WHEN GIVEN IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND IMPAIRED RENAL FUNCTION

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-008

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

A Phase I in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Amgen

Protocol Number
20150161

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Blue Bird CRB-401

Protocol Number
Blue Bird CRB-401

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION MM-003)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A PHASE 1 MULTI-CENTER, OPEN-LABEL, DOSE ESCALATION STUDY TO DETERMINE THE PHARMACOKINETICS AND SAFETY OF POMALIDOMIDE WHEN GIVEN IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND IMPAIRED RENAL FUNCTION

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-008

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

A Phase I in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Amgen

Protocol Number
20150161

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Blue Bird CRB-401

Protocol Number
Blue Bird CRB-401

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION MM-003)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A PHASE 1 MULTI-CENTER, OPEN-LABEL, DOSE ESCALATION STUDY TO DETERMINE THE PHARMACOKINETICS AND SAFETY OF POMALIDOMIDE WHEN GIVEN IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND IMPAIRED RENAL FUNCTION

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-008

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

A Phase I in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Amgen

Protocol Number
20150161

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Blue Bird CRB-401

Protocol Number
Blue Bird CRB-401

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION MM-003)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A PHASE 1 MULTI-CENTER, OPEN-LABEL, DOSE ESCALATION STUDY TO DETERMINE THE PHARMACOKINETICS AND SAFETY OF POMALIDOMIDE WHEN GIVEN IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND IMPAIRED RENAL FUNCTION

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-008

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

A Phase I in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Amgen

Protocol Number
20150161

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Blue Bird CRB-401

Protocol Number
Blue Bird CRB-401

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION MM-003)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A PHASE 1 MULTI-CENTER, OPEN-LABEL, DOSE ESCALATION STUDY TO DETERMINE THE PHARMACOKINETICS AND SAFETY OF POMALIDOMIDE WHEN GIVEN IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND IMPAIRED RENAL FUNCTION

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-008

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

A Phase I in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Amgen

Protocol Number
20150161

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Blue Bird CRB-401

Protocol Number
Blue Bird CRB-401

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION MM-003)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A PHASE 1 MULTI-CENTER, OPEN-LABEL, DOSE ESCALATION STUDY TO DETERMINE THE PHARMACOKINETICS AND SAFETY OF POMALIDOMIDE WHEN GIVEN IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND IMPAIRED RENAL FUNCTION

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-008

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

A Phase I in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Amgen

Protocol Number
20150161

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Blue Bird CRB-401

Protocol Number
Blue Bird CRB-401

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION MM-003)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A PHASE 1 MULTI-CENTER, OPEN-LABEL, DOSE ESCALATION STUDY TO DETERMINE THE PHARMACOKINETICS AND SAFETY OF POMALIDOMIDE WHEN GIVEN IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND IMPAIRED RENAL FUNCTION

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-008

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

A Phase I in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Amgen

Protocol Number
20150161

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Blue Bird CRB-401

Protocol Number
Blue Bird CRB-401

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION MM-003)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A PHASE 1 MULTI-CENTER, OPEN-LABEL, DOSE ESCALATION STUDY TO DETERMINE THE PHARMACOKINETICS AND SAFETY OF POMALIDOMIDE WHEN GIVEN IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND IMPAIRED RENAL FUNCTION

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-008

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

A Phase I in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Amgen

Protocol Number
20150161

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Blue Bird CRB-401

Protocol Number
Blue Bird CRB-401

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION MM-003)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A PHASE 1 MULTI-CENTER, OPEN-LABEL, DOSE ESCALATION STUDY TO DETERMINE THE PHARMACOKINETICS AND SAFETY OF POMALIDOMIDE WHEN GIVEN IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND IMPAIRED RENAL FUNCTION

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-008

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

A Phase I in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Amgen

Protocol Number
20150161

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Blue Bird CRB-401

Protocol Number
Blue Bird CRB-401

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION MM-003)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A PHASE 1 MULTI-CENTER, OPEN-LABEL, DOSE ESCALATION STUDY TO DETERMINE THE PHARMACOKINETICS AND SAFETY OF POMALIDOMIDE WHEN GIVEN IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND IMPAIRED RENAL FUNCTION

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-008

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

A Phase I in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Amgen

Protocol Number
20150161

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Blue Bird CRB-401

Protocol Number
Blue Bird CRB-401

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION MM-003)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A PHASE 1 MULTI-CENTER, OPEN-LABEL, DOSE ESCALATION STUDY TO DETERMINE THE PHARMACOKINETICS AND SAFETY OF POMALIDOMIDE WHEN GIVEN IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND IMPAIRED RENAL FUNCTION

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-008

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

A Phase I in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Amgen

Protocol Number
20150161

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Blue Bird CRB-401

Protocol Number
Blue Bird CRB-401

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION MM-003)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A PHASE 1 MULTI-CENTER, OPEN-LABEL, DOSE ESCALATION STUDY TO DETERMINE THE PHARMACOKINETICS AND SAFETY OF POMALIDOMIDE WHEN GIVEN IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND IMPAIRED RENAL FUNCTION

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-008

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

A Phase I in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Amgen

Protocol Number
20150161

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Blue Bird CRB-401

Protocol Number
Blue Bird CRB-401

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION MM-003)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A PHASE 1 MULTI-CENTER, OPEN-LABEL, DOSE ESCALATION STUDY TO DETERMINE THE PHARMACOKINETICS AND SAFETY OF POMALIDOMIDE WHEN GIVEN IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND IMPAIRED RENAL FUNCTION

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-008

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

A Phase I in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Amgen

Protocol Number
20150161

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Blue Bird CRB-401

Protocol Number
Blue Bird CRB-401

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION MM-003)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A PHASE 1 MULTI-CENTER, OPEN-LABEL, DOSE ESCALATION STUDY TO DETERMINE THE PHARMACOKINETICS AND SAFETY OF POMALIDOMIDE WHEN GIVEN IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND IMPAIRED RENAL FUNCTION

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-008

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

A Phase I in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Amgen

Protocol Number
20150161

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Blue Bird CRB-401

Protocol Number
Blue Bird CRB-401

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION MM-003)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A PHASE 1 MULTI-CENTER, OPEN-LABEL, DOSE ESCALATION STUDY TO DETERMINE THE PHARMACOKINETICS AND SAFETY OF POMALIDOMIDE WHEN GIVEN IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND IMPAIRED RENAL FUNCTION

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-008

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

A Phase I in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Amgen

Protocol Number
20150161

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Blue Bird CRB-401

Protocol Number
Blue Bird CRB-401

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION MM-003)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A PHASE 1 MULTI-CENTER, OPEN-LABEL, DOSE ESCALATION STUDY TO DETERMINE THE PHARMACOKINETICS AND SAFETY OF POMALIDOMIDE WHEN GIVEN IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND IMPAIRED RENAL FUNCTION

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-008

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

A Phase I in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Amgen

Protocol Number
20150161

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Blue Bird CRB-401

Protocol Number
Blue Bird CRB-401

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION MM-003)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A PHASE 1 MULTI-CENTER, OPEN-LABEL, DOSE ESCALATION STUDY TO DETERMINE THE PHARMACOKINETICS AND SAFETY OF POMALIDOMIDE WHEN GIVEN IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND IMPAIRED RENAL FUNCTION

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-008

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

A Phase I in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Amgen

Protocol Number
20150161

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Blue Bird CRB-401

Protocol Number
Blue Bird CRB-401

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION MM-003)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A PHASE 1 MULTI-CENTER, OPEN-LABEL, DOSE ESCALATION STUDY TO DETERMINE THE PHARMACOKINETICS AND SAFETY OF POMALIDOMIDE WHEN GIVEN IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND IMPAIRED RENAL FUNCTION

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-008

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

A Phase I in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Amgen

Protocol Number
20150161

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Blue Bird CRB-401

Protocol Number
Blue Bird CRB-401

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION MM-003)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A PHASE 1 MULTI-CENTER, OPEN-LABEL, DOSE ESCALATION STUDY TO DETERMINE THE PHARMACOKINETICS AND SAFETY OF POMALIDOMIDE WHEN GIVEN IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND IMPAIRED RENAL FUNCTION

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-008

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

A Phase I in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Amgen

Protocol Number
20150161

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Blue Bird CRB-401

Protocol Number
Blue Bird CRB-401

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION MM-003)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A PHASE 1 MULTI-CENTER, OPEN-LABEL, DOSE ESCALATION STUDY TO DETERMINE THE PHARMACOKINETICS AND SAFETY OF POMALIDOMIDE WHEN GIVEN IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND IMPAIRED RENAL FUNCTION

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-008

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

A Phase I in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Amgen

Protocol Number
20150161

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Blue Bird CRB-401

Protocol Number
Blue Bird CRB-401

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION MM-003)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A PHASE 1 MULTI-CENTER, OPEN-LABEL, DOSE ESCALATION STUDY TO DETERMINE THE PHARMACOKINETICS AND SAFETY OF POMALIDOMIDE WHEN GIVEN IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND IMPAIRED RENAL FUNCTION

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-008

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

A Phase I in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Amgen

Protocol Number
20150161

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Blue Bird CRB-401

Protocol Number
Blue Bird CRB-401

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION MM-003)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A PHASE 1 MULTI-CENTER, OPEN-LABEL, DOSE ESCALATION STUDY TO DETERMINE THE PHARMACOKINETICS AND SAFETY OF POMALIDOMIDE WHEN GIVEN IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND IMPAIRED RENAL FUNCTION

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-008

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

A Phase I in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Amgen

Protocol Number
20150161

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Blue Bird CRB-401

Protocol Number
Blue Bird CRB-401

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION MM-003)

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Sponsor
Glenmark

Protocol Number
Glenmark GBR 1342-101

To Learn More Call
201-510-0910

A PHASE 1 MULTI-CENTER, OPEN-LABEL, DOSE ESCALATION STUDY TO DETERMINE THE PHARMACOKINETICS AND SAFETY OF POMALIDOMIDE WHEN GIVEN IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND IMPAIRED RENAL FUNCTION

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-008

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Mount Holly, Sparta

Sponsor
Merck

Protocol Number
3475-185

To Learn More Call
201-510-0910

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies Study Name: STORM (Selinexor Treatment of Refractory Myeloma)

Sponsor
Karyopharm

Protocol Number
KCP-330-012

To Learn More Call
201-510-0910

A Phase I in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Amgen

Protocol Number
20150161

To Learn More Call
201-510-0910

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver

Sponsor
MILLENIUM

Protocol Number
C16021

To Learn More Call
201-510-0910

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Sponsor
Blue Bird

Protocol Number
Blue Bird CRB-402

To Learn More Call
201-510-0910

A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Blue Bird CRB-401

Protocol Number
Blue Bird CRB-401

To Learn More Call